QQQ   354.77 (+0.46%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
QQQ   354.77 (+0.46%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
QQQ   354.77 (+0.46%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
QQQ   354.77 (+0.46%)
AAPL   181.44 (+0.48%)
MSFT   327.33 (+0.64%)
META   264.99 (+0.15%)
GOOGL   122.53 (+0.32%)
AMZN   123.83 (-0.34%)
TSLA   246.69 (+5.04%)
NVDA   389.64 (+1.18%)
NIO   7.92 (+1.67%)
BABA   85.83 (-0.36%)
AMD   124.75 (+3.06%)
T   16.01 (-0.37%)
F   13.82 (+1.77%)
MU   65.29 (-0.05%)
CGC   0.67 (-3.31%)
GE   105.71 (-0.34%)
DIS   91.81 (-0.78%)
AMC   4.73 (+1.07%)
PFE   38.94 (-0.38%)
PYPL   63.53 (-1.11%)
NFLX   423.99 (+3.57%)
NASDAQ:UBX

Unity Biotechnology (UBX) Stock Forecast, Price & News

$3.42
-0.12 (-3.39%)
(As of 01:19 PM ET)
Compare
Today's Range
$3.27
$3.61
50-Day Range
$1.49
$3.54
52-Week Range
$1.46
$18.50
Volume
95,237 shs
Average Volume
360,797 shs
Market Capitalization
$49.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75

Unity Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
99.7% Upside
$6.75 Price Target
Short Interest
Healthy
7.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$15,097 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.41) to ($3.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

274th out of 986 stocks

Pharmaceutical Preparations Industry

119th out of 481 stocks


UBX stock logo

About Unity Biotechnology (NASDAQ:UBX) Stock

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

UBX Stock News Headlines

Wedbush Sticks to Its Buy Rating for Unity Biotechnology (UBX)
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
Unity Biotechnology (UBX) Gets a Buy from H.C. Wainwright
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Where Unity Biotechnology Stands With Analysts
Unity Biotechnology (UBX) Gets a Buy from Wedbush
Unity Biotechnology (UBX) Receives a Rating Update from a Top Analyst
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $5.00
Expert Ratings for Unity Biotechnology
See More Headlines

UBX Price History

UBX Company Calendar

Last Earnings
5/09/2023
Today
6/09/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:UBX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.75
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+95.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-59,930,000.00
Pretax Margin
-21,981.78%

Debt

Sales & Book Value

Annual Sales
$236,000.00
Book Value
$4.71 per share

Miscellaneous

Free Float
13,661,000
Market Cap
$49.56 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Dr. Anirvan Ghosh Ph.D. (Age 59)
    CEO & Director
    Comp: $1.08M
  • Dr. Nathaniel E. David A.B. (Age 55)
    Ph.D., Co-Founder & Exec. Director
    Comp: $40k
  • Ms. Lynne Marie Sullivan (Age 56)
    CFO & Head of Corp. Devel.
    Comp: $730.82k
  • Dr. Jan M. van Deursen
    Founder
  • Dr. Judith Campisi Ph.D.
    Founder
  • Mr. Daohong Zhou M.D.
    Founder
  • Mr. Nathan Guz Ph.D.
    VP of Operations
  • Mr. Alexander Azoy (Age 47)
    Chief Accounting Officer & Principal Accounting Officer
  • Dr. Przemyslaw Sapieha Ph.D.
    Chief Scientist
  • Mr. Alexander Hieu Nguyen J.D. (Age 46)
    Gen. Counsel & Corp. Sec.













UBX Stock - Frequently Asked Questions

Should I buy or sell Unity Biotechnology stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UBX shares.
View UBX analyst ratings
or view top-rated stocks.

What is Unity Biotechnology's stock price forecast for 2023?

5 brokers have issued twelve-month price targets for Unity Biotechnology's stock. Their UBX share price forecasts range from $5.00 to $10.00. On average, they predict the company's stock price to reach $6.75 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for UBX
or view top-rated stocks among Wall Street analysts.

How have UBX shares performed in 2023?

Unity Biotechnology's stock was trading at $2.74 on January 1st, 2023. Since then, UBX shares have increased by 25.9% and is now trading at $3.45.
View the best growth stocks for 2023 here
.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 952,200 shares, a decrease of 17.2% from the April 30th total of 1,150,000 shares. Based on an average daily volume of 417,800 shares, the days-to-cover ratio is presently 2.3 days. Approximately 7.4% of the company's stock are sold short.
View Unity Biotechnology's Short Interest
.

When is Unity Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our UBX earnings forecast
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.34.

When did Unity Biotechnology's stock split?

Unity Biotechnology shares reverse split on the morning of Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (2.01%), Geode Capital Management LLC (0.86%), BlackRock Inc. (0.75%), ExodusPoint Capital Management LP (0.65%), Renaissance Technologies LLC (0.54%) and Dimensional Fund Advisors LP (0.47%). Insiders that own company stock include Anirvan Ghosh, Jamie Dananberg and Nathaniel E David.
View institutional ownership trends
.

How do I buy shares of Unity Biotechnology?

Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $3.45.

How much money does Unity Biotechnology make?

Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $49.56 million and generates $236,000.00 in revenue each year. The company earns $-59,930,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis.

How can I contact Unity Biotechnology?

The official website for the company is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192 or via email at ir@unitybiotechnology.com.

This page (NASDAQ:UBX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -